A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 1, 2008, Pages 179-186

  Kim, Yu Mi ^a   Lim, Jeong Ok ^a   Kim, Hong Kyun ^a   Kim, Si Yeol ^a   Shin, Jae Pil ^a  

^a Kyungpook National University   (South Korea)

Author keywords

Intrascleral implant; One side coating; Poly(d,l lactide) (PLA); Triamcinolone acetonide

Indexed keywords

POLYLACTIDE; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CHOROID; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG COATING; DRUG DELIVERY SYSTEM; ELECTRORETINOGRAPHY; HISTOLOGY; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; INTRASCLERAL DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; OPHTHALMOSCOPY; POSTERIOR EYE CHAMBER; RABBIT; RETINA; SCLERA; SLIT LAMP; SLOW RELEASE FORMULATION; SUSTAINED RELEASE FORMULATION; VITREOUS BODY;

ADRENAL CORTEX HORMONES; ANIMALS; AQUEOUS HUMOR; CHEMISTRY, PHARMACEUTICAL; CHOROID; COATED MATERIALS, BIOCOMPATIBLE; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG COMPOUNDING; DRUG IMPLANTS; KINETICS; LACTIC ACID; MOLECULAR WEIGHT; POLYMERS; RABBITS; RETINA; SCLERA; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 50149122229     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.04.023     Document Type: Article

References (34)

1. Antcliff R.J., Spalton D.J., Stanford M.R., Graham E.M., ffytche T.J., and Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study. Ophthalmology 108 (2001) 765-772
2. Young S., Larkin G., Branley M., and Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Experiment. Ophthalmol. 29 (2001) 2-6
3. Jonas J.B., and Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am. J. Ophthalmol. 132 (2001) 425-427
4. Martidis A., Duker J.S., Greenberg P.B., Rogers A.H., Puliafito C.A., Reichel E., and Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109 (2002) 920-927
5. Greenberg P.B., Martidis A., Rogers A.H., Duker J.S., and Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br. J. Ophthalmol. 86 (2002) 247-248
6. Zhou T., Lewis H., Foster R.E., and Schwendeman S.P. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release. 55 (1998) 281-295
7. Danis R.P., Ciulla T.A., Pratt L.M., and Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20 (2000) 244-250
8. Gillies M.C., Simpson J.M., Luo W., Penfold P., Hunyor A.B., Chua W., Mitchel P., and Billson F. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch. Ophthalmol. 121 (2003) 667-673
9. Ahmed I., and Patton T.F. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26 (1985) 584-587
10. Ahmed I., Gokhale R.D., Shah M.V., and Patton T.F. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J. Pharm. Sci. 76 (1987) 583-586
11. Lang J.C. Ocular drug delivery conventional ocular formulations. Adv. Drug. Delivery Rev. 16 (1995) 39-43
12. Jonas J.B. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol. Scand. 83 (2005) 645-663
13. Olsen T.W., Aaberg S.Y., Geroski D.H., and Edelhauser H.F. Human sclera: thickness and surface area. Am. J. Ophthalmol. 125 (1998) 237-241
14. Ambati J., and Adamis A.P. Transscleral drug delivery to the retina and choroid. Prog. Retin. Eye Res. 21 (2002) 145-151
15. Prausnitz M.R., and Noonan J.S. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 87 (1998) 1479-1488
16. Ambati J., Canakis C.S., Miller J.W., Gragoudas E.S., Edwards A., Weissgold D.J., Kim I., Delori F.C., and Adamis A.P. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 41 (2000) 1181-1185
17. Mora P., Eperon S., Felt-Baeyens O., Gurny R., Sagodira S., Breton P., and Guex-Crosier Y. Trans-scleral diffusion of triamcinolone acetonide. Curr. Eye Res. 30 (2005) 355-361
18. Kim S.H., Lutz R.J., Wang N.S., and Robinson M.R. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic. Res. 39 (2007) 244-254
19. Robinson M.R., Lee S.S., Kim H., Kim S., Lutz R.J., Galban C., Bungay P.M., Yuan P., S Wang N., Kim J., and Csaky K.G. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res. 82 (2006) 479-487
20. Pontes de Carvalho R.A., Krausse M.L., Murphree A.L., Schmitt E.E., Campochiaro P.A., and Maumenee I.H. Delivery from episcleral exoplants. Invest. Ophthalmol. Vis. Sci. 47 (2006) 4532-4539
21. Okabe J., Kimura H., Kunou N., Okabe K., Kato A., and Ogura Y. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci. 44 (2003) 740-744
22. Kunou N., Ogura Y., Honda Y., Hyon S.H., and Ikada Y. Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate. J. Biomed. Mater. Res. 51 (2000) 635-641
23. Kimura H., and Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica 215 (2001) 143-155
24. Okabe K., Kimura H., Okabe J., Kato A., Kunou N., and Ogura Y. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2702-2707
25. Pitkanen L., Ranta V.P., Moilanen H., and Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci. 46 (2005) 641-646
26. Scholes G.N., O'Brien W.J., Abrams G.W., and Kubicek M.F. Clearance of triamcinolone from vitreous. Arch. Ophthalmol. 103 (1985) 1567-1569
27. Mason III J.O., Somaiya M.D., and Singh R.J. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina 24 (2004) 900-904
28. Chin H.S., Park T.S., Moon Y.S., and Oh J.H. Difference in clearance of intravitreal triamcinolone between vitrectomized and non-vitrectomized eyes. Retina 25 (2005) 556-560
29. Beer P.M., Bakri S.J., Singh R.J., Liu W., Peters III G.B., and Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110 (2003) 681-686
30. Felt-Baeyens O., Eperon S., Mora P., Limal D., Sagodira S., Breton P., Simonazzi B., Bossy-Nobs L., Guex-Crosier Y., and Gurny R. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int. J. Pharm. 322 (2006) 6-12
31. Olsen T.W., Edelhauser H.F., Lim J.I., and Geroski D.H. Human sclera permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Vis. Sci. 36 (1995) 1893-1903
32. Okabe K., Kimura H., Okabe J., and Ogura Y. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants. Retina 27 (2007) 770-777
33. Prince J.H., Diesem C.D., Eglitis I., and Ruskell G.L. The rabbit. In: Prince J.H. (Ed). Anatomy and Histology of the Eye and Orbit in Domestic Animals (1960), Charles C Thomas, Springfield, IL 268
34. Morrison V.L., Koh H.J., Cheng L., Bessho K., Davidson M.C., and Freeman W.R. Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina 26 (2006) 339-344